2011 Scrip 100: Fine-tuning the epigenetic ecosystem
This article was originally published in Scrip
Ten years on and the human genome has turned out not to be quite as useful as was once hoped it might be. We didn't know that then, of course. In the deep barren void of 1990s human biology, any dim glimmer appears to bathe every question in light. What the human genome sequence and its variation among individuals demonstrated all too clearly in a Rumsfeldian manner, is that there are more ways of not knowing about human health and disease than anyone could have imagined a decade ago.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.